Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Assessment and Management of Neuromuscular Disorders

Initial Diagnostic Evaluation

  • The American Academy of Neurology recommends measuring serum creatine kinase (CK) as the first-line screening test for suspected neuromuscular disease, followed by genetic testing for dystrophin mutations before considering muscle biopsy 1, 2
  • In male children, delayed walking beyond 16-18 months, frequent falls, difficulty climbing stairs, or positive Gowers' sign are clinical red flags requiring immediate assessment 1, 2
  • Unexplained elevated transaminases in any male child should be evaluated with CK testing to rule out muscular dystrophy before proceeding to liver biopsy 1, 2

Respiratory Management

  • The American Thoracic Society recommends performing pulmonary function testing (PFT) every 6 months in patients at risk of respiratory complications, with respiratory failure being the leading cause of mortality in neuromuscular disease 3, 4, 5
  • At each visit, measure forced vital capacity (FVC) or slow vital capacity (SVC), maximum inspiratory/expiratory pressure (MIP/MEP) or sniff nasal inspiratory pressure (SNIP), and peak cough flow (PCF) 3, 4
  • Noninvasive ventilation (NIV) should be initiated when diagnostic tests show declining FVC, reduced MIP/MEP, abnormal overnight oximetry, or evidence of sleep-disordered breathing on polysomnography 3, 4, 5

Cardiac Management

  • The American Heart Association recommends obtaining a baseline echocardiogram at diagnosis or by age 6 years, then repeating at maximum 24-month intervals until age 10, and annually thereafter, with early intervention using ACE inhibitors and beta-blockers even if asymptomatic 1, 6, 7
  • ACE inhibitors and beta-blockers should be initiated at the first sign of cardiac dysfunction, even if the patient is asymptomatic 8, 6, 7

Neuromuscular Function Monitoring

  • The American Academy of Physical Medicine and Rehabilitation recommends assessing muscle strength using manual muscle testing and quantitative myometry every 6 months during the ambulatory phase, combined with standardized timed function tests 7
  • Timed function tests, such as the 10-meter walk, timed Gowers' maneuver, 4-stair climb, rise from chair, and 6-minute walk test, should be performed every 6 months 7

Pharmacological Management

  • The American Academy of Neurology recommends initiating glucocorticoids (prednisone/prednisolone 0.75 mg/kg daily or deflazacort 0.9 mg/kg daily) as the only medications proven to slow decline in muscle strength and function in Duchenne muscular dystrophy 7

Orthopedic and Rehabilitation Management

  • The American Academy of Physical Medicine and Rehabilitation recommends prescribing ankle-foot orthoses when ankle dorsiflexion weakness develops to prolong ambulation 7
  • Surgical intervention, such as iliotibial band lengthening or Achilles tendon release, should be considered when contractures limit function 7

Psychosocial and Cognitive Management

  • The American Academy of Pediatrics recommends performing comprehensive neuropsychological assessment at diagnosis and before school entry to establish baseline cognitive function 7, 9
  • Regular screening for depression, anxiety, obsessive-compulsive disorder, and attention-deficit hyperactivity disorder is essential, with consideration of selective serotonin reuptake inhibitors for moderate to severe symptoms 7, 9

Multidisciplinary Care Coordination

  • The American Academy of Pediatrics recommends designating a care coordinator with sufficient clinical training to serve as the family's point of contact, schedule appointments, and facilitate communication between clinicians 7
  • A multidisciplinary team approach, including neurology, cardiology, pulmonology, physical therapy, occupational therapy, speech therapy, nutrition, psychology, and genetics, is essential for comprehensive care 1, 6

Nutrition and Gastrointestinal Management

  • The American Academy of Pediatrics recommends monitoring for normal weight gain for age with nutritional assessment for over/underweight status 1, 6
  • Attention to possible dysphagia is crucial as the disease progresses, with consideration of special weight scales and height measurements using arm-span measurements in patients with severe scoliosis 1, 6

Palliative and Supportive Care

  • The American Heart Association recommends integrating palliative care early for pain management, emotional and spiritual support, and guidance with treatment decisions, as this improves quality of life and may prolong survival 8, 7
  • Palliative care should be considered for patients admitted with heart failure, especially those with multiple admissions, and included in the evaluation of all patients being considered for mechanical circulatory support or cardiac transplantation 8

Evidence‑Based Monitoring and Intervention Strategies for Limb‑Girdle Muscular Dystrophy

Neuromuscular Assessment

  • Perform manual muscle testing (MRC scale) and quantitative myometry every six months, together with standardized timed functional tests (10‑m walk, Gowers’ maneuver, 4‑stair climb, rise from chair, 6‑minute walk) to track disease progression. 10
  • Conduct goniometric range‑of‑motion examinations of hip, knee, ankle, iliotibial band, hamstrings, gastrocnemius, elbow, wrist, and long‑finger flexors every six months to detect emerging hypo‑extensibility and contractures that may impair function. 10

Cardiac Management

  • Initiate ACE‑inhibitor and beta‑blocker therapy at the first objective sign of cardiac dysfunction, even if the patient is asymptomatic, to slow progression of cardiomyopathy. 11
  • Perform baseline and periodic electrocardiogram and Holter monitoring to identify arrhythmias or conduction abnormalities early in the disease course. 11

Respiratory Management

  • Measure forced vital capacity, maximal inspiratory/expiratory pressures, and peak cough flow every six months in non‑ambulatory patients and every six‑to‑twelve months in ambulatory patients; record the patient’s testing position for consistent longitudinal comparison. 12
  • Screen at each visit for symptoms of sleep‑disordered breathing and recurrent chest infections, recognizing that respiratory failure is the leading cause of mortality in neuromuscular disease and becomes more likely as upper‑limb weakness progresses (e.g., Brooke score ≥ 3). 12
  • Ensure all patients receive vaccinations according to national immunization schedules to reduce the risk of respiratory infections. 12

Rehabilitation and Orthopedic Interventions

  • Encourage supervised aerobic exercise programs tailored to LGMD subtypes (e.g., LGMD2I, 2L, 2A) to improve oxidative capacity and muscle function while avoiding intense eccentric loading. 13
  • Provide adaptive devices (e.g., specialized keyboards, wheelchair controls) and consider orthotic or splinting interventions to support activities of daily living and maintain independence. 10
  • Consider surgical release procedures such as iliotibial band lengthening or Achilles tendon release when contractures significantly limit mobility or wheelchair positioning. 13

Nutritional and Dysphagia Monitoring

  • Weigh patients at every visit using wheelchair‑compatible scales and perform a nutritional assessment to identify under‑ or over‑nutrition. 13
  • Evaluate for dysphagia progressively, especially in individuals with bulbar involvement, to guide dietary modifications and safe swallowing strategies. [13][12]

Functional and Psychosocial Surveillance

  • Assess functional status in self‑care, writing, computer use, and wheelchair control regularly to guide targeted assistive technology and environmental adaptations. 10
  • Monitor participation in school and community settings to support independence and social development. [13][10]

REFERENCES

2

Diagnostic Guidelines for Muscular Dystrophy [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

7

Duchenne Muscular Dystrophy Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

9

Management of Myotonic Dystrophy [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025